<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03913338</url>
  </required_header>
  <id_info>
    <org_study_id>154/14</org_study_id>
    <nct_id>NCT03913338</nct_id>
  </id_info>
  <brief_title>Laser In-situ Keratomileusis With Crosslinking Compared to Conventional LASIK in Patients With High Myopia</brief_title>
  <official_title>A Controlled Evaluation of the Safety and Efficacy of Laser In-situ Keratomileusis With Crosslinking (XtraLASIK) Compared to Conventional LASIK (convLASIK) in Patients With High Myopia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Clinic Frankfurt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avedro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Clinic Frankfurt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety and efficacy of a treatment regimen
      for high myopia and myopic astigmatism: LASIK followed by crosslinking performed with the KXL
      Crosslinking-System and VibeX Xtra (Riboflavin Ophthalmic Solution, Avedro, USA), as compared
      to LASIK alone, with regards to regression of refractive outcome, as measured by manifest
      refraction spherical equivalent (MRSE) and keratometry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a controlled study of the safety and efficacy of the KXL System and VibeX Xtra
      (Riboflavin Ophthalmic Solution, Avedro, USA) for performing crosslinking in eyes undergoing
      LASIK for high myopia or myopic astigmatism. Each subject will have bilateral LASIK performed
      and one eye will be randomized to undergo LASIK followed by crosslinking.

      Subjects will undergo bilateral LASIK. Following randomisation one eye of each subject will
      be treated with VibeX Xtra (Riboflavin Ophthalmic Solution) following LASIK and will be
      irradiated with the KXL System at 30 mW/cm2 intensity for 90 seconds continuous UV-A light
      treatment for a total radiant exposure of 2.7 J /cm2.

      All eyes will be assessed at 1 day, 1, 3, 6, and 12 months after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2014</start_date>
  <completion_date type="Actual">July 3, 2018</completion_date>
  <primary_completion_date type="Actual">July 3, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, intra-patient controlled, clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>uncorrected distant visual acuity</measure>
    <time_frame>12 months postoperative</time_frame>
    <description>uncorrected distant visual acuity (logarithmic minimum angle of resolution)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>best spectacle corrected distant visual acuity</measure>
    <time_frame>12 months postoperative</time_frame>
    <description>best spectacle corrected distant visual acuity (logarithmic minimum angle of resolution)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>spherical equivalent</measure>
    <time_frame>12 months postoperative</time_frame>
    <description>spherical equivalent (diopter)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endothelial cell count</measure>
    <time_frame>12 months postoperative</time_frame>
    <description>endothelial cell count (number of cells/ mm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal thickness</measure>
    <time_frame>12 months postoperative</time_frame>
    <description>Corneal thickness (micro millimeter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective visual quality</measure>
    <time_frame>12 months postoperative</time_frame>
    <description>Questionnaire regarding subjective optical quality (scale from 0 - 100; 0 = minimal, 100 = maximum)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Myopia</condition>
  <condition>Myopic Astigmatism</condition>
  <condition>Crosslinking</condition>
  <condition>Corneal Ectasia</condition>
  <condition>Myopic Regression</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>LASIK followed by intraoperative application of riboflavin under the flap and crosslinking after reposition of the flap.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>LASIK only</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LasikXtra</intervention_name>
    <description>By randomized selection, one eye was treated with the LASIK Xtra procedure that consists of fs-LASIK treatment combined with intraoperative accelerated continuous UV-riboflavin crosslinking. After laser ablation, the corneal bed under the flap was coated with riboflavin, rinsed with saline solution, and after 90 seconds the corneal flap was repositioned. The eye was irradiated at 30 mW/cm2 for 90 seconds with continuous UVA.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>LASIK</intervention_name>
    <description>Femtosecond-assisted preparation of a corneal flap and subsequently excimer-laser ablation of corneal stroma. Repositioning of the corneal flap and installation of a therapeutic contact lens.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  eligible for bilateral myopic fs-LASIK with -6.00 to -12.00 D (diopters) with a
             maximum of 5.00 D astigmatism

          -  age &gt; 18 years

          -  provided written informed consent

          -  difference between the MRSE and cycloplegic SE less than 0.75 D

          -  MRSE needed to be stable for the last 12 months (&lt;0.5 D).

        Exclusion Criteria:

          -  prior corneal surgery,

          -  forme fruste or manifest keratoconus,

          -  history of corneal scarring, melting, ulceration

          -  repeating inflammations of the eye

          -  taking vitamin C 1 week prior to the treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kohnen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Augenklinik des Universitätsklinikum der Goethe Unveristät Frankfurt am Main</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of ophthalmology University clinic Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2019</study_first_posted>
  <last_update_submitted>April 10, 2019</last_update_submitted>
  <last_update_submitted_qc>April 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Clinic Frankfurt</investigator_affiliation>
    <investigator_full_name>Professor Dr. med. Thomas Kohnen</investigator_full_name>
    <investigator_title>Head of Ophthalmology, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

